News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
71,180 Results
Type
Article (1923)
Company Profile (3)
Press Release (69254)
Section
Business (21470)
Career Advice (9)
Deals (4552)
Drug Development (8160)
FDA (1804)
Job Trends (800)
News (37031)
Policy (3562)
Tag
Academia (94)
Allergies (10)
Alliances (8172)
ALS (9)
Alzheimer's disease (143)
Antibody-drug conjugate (ADC) (28)
Approvals (1863)
Artificial intelligence (19)
Autoimmune disease (3)
Automation (1)
Bankruptcy (8)
Best Places to Work (585)
Biosimilars (45)
Biotechnology (5)
Bladder cancer (21)
Brain cancer (4)
Breast cancer (38)
Cancer (365)
Cardiovascular disease (12)
Career advice (9)
CAR-T (9)
Cell therapy (38)
Cervical cancer (2)
Clinical research (7241)
Collaboration (164)
Compensation (16)
Complete response letters (4)
COVID-19 (192)
C-suite (38)
Cystic fibrosis (4)
Data (402)
Depression (7)
Diabetes (26)
Diagnostics (611)
Digital health (2)
Drug discovery (24)
Duchenne muscular dystrophy (23)
Earnings (7818)
Events (7194)
Executive appointments (56)
FDA (2085)
Fibrodysplasia Ossificans Progressiva (1)
Funding (95)
Gene editing (4)
Generative AI (1)
Gene therapy (27)
GLP-1 (60)
Government (233)
Grass and pollen (1)
Guidances (33)
Healthcare (1079)
HIV (1)
Huntington's disease (2)
IgA nephropathy (12)
Immunology and inflammation (4)
Indications (7)
Infectious disease (202)
Inflammatory bowel disease (21)
Influenza (8)
Intellectual property (23)
IPO (1635)
Job creations (241)
Job search strategy (9)
Layoffs (6)
Legal (953)
Liver cancer (17)
Lung cancer (70)
Lymphoma (25)
Manufacturing (56)
MASH (10)
Medical device (1137)
Medtech (1139)
Mergers & acquisitions (3050)
Metabolic disorders (59)
Multiple sclerosis (12)
NASH (1)
Neurodegenerative disease (14)
Neuroscience (226)
NextGen: Class of 2025 (219)
Non-profit (62)
Obesity (19)
Opinion (2)
Ovarian cancer (17)
Pain (5)
Pancreatic cancer (11)
Parkinson's disease (25)
Partnered (2)
Patents (37)
Patient recruitment (30)
Peanut (1)
People (5032)
Pharmaceutical (3)
Pharmacy benefit managers (2)
Phase I (1957)
Phase II (3049)
Phase III (2737)
Pipeline (279)
Policy (1)
Postmarket research (241)
Preclinical (681)
Press Release (2)
Prostate cancer (14)
Radiopharmaceuticals (22)
Rare diseases (38)
Real estate (603)
Regulatory (2732)
Reports (6)
Research institute (97)
RNA editing (1)
RSV (2)
Schizophrenia (12)
Series A (20)
Series B (15)
Service/supplier (1)
Sickle cell disease (3)
Spinal muscular atrophy (4)
Sponsored (1)
Startups (423)
Stomach cancer (1)
Supply chain (11)
Vaccines (35)
Venture capital (2)
Weight loss (4)
Women's health (2)
Date
Today (8)
Last 7 days (35)
Last 30 days (189)
Last 365 days (2663)
2025 (2071)
2024 (3253)
2023 (3814)
2022 (7013)
2021 (6372)
2020 (5872)
2019 (3867)
2018 (3013)
2017 (3562)
2016 (3176)
2015 (4030)
2014 (3020)
2013 (2604)
2012 (2775)
2011 (2903)
2010 (2663)
Location
Africa (83)
Alabama (3)
Arizona (9)
Asia (21723)
Australia (2452)
California (515)
Canada (308)
China (277)
Colorado (4)
Connecticut (18)
Delaware (4)
Europe (12777)
Florida (46)
Georgia (11)
Illinois (22)
India (22)
Indiana (11)
Japan (164)
Kansas (5)
Louisiana (1)
Maine (4)
Maryland (97)
Massachusetts (366)
Michigan (4)
Minnesota (32)
Missouri (3)
Nebraska (1)
Nevada (4)
New Jersey (304)
New York (191)
North Carolina (73)
Northern California (202)
Ohio (3)
Oregon (1)
Pennsylvania (88)
Rhode Island (1)
South America (107)
Southern California (245)
Tennessee (1)
Texas (44)
United States (1919)
Utah (16)
Virginia (37)
Washington D.C. (3)
Washington State (30)
Wisconsin (6)
71,180 Results for "evogene ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Evogene Schedules First Quarter 2024 Financial Results Release
Evogene Ltd., a leading computational biology company targeting to revolutionize life-science product discovery and development, announced that it will release its financial results for the first quarter of 2024, on Thursday, May 23, 2024.
May 9, 2024
·
2 min read
Business
Evogene Reports First Quarter 2024 Financial Results
Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize the development of life-science-based products, today announced its financial results for the first quarter period ended March 31, 2024.
May 23, 2024
·
18 min read
Business
Evogene Reports Fourth Quarter and Full Year 2023 Financial Results
Evogene Ltd. today announced its financial results for the fourth quarter and full-year period ending December 31, 2023.
March 7, 2024
·
19 min read
Press Releases
Tenpoint Therapeutics, Ltd. to Participate in Four Upcoming Investor Conferences
October 14, 2025
·
1 min read
Press Releases
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025
October 14, 2025
·
10 min read
Business
Evogene Schedules Fourth Quarter 2023 Financial Results Release & Conference Call for March 7th, 2024
Evogene Ltd announced today that it will release its financial results for the third quarter of 2023 on Thursday, March 7th, 2024.
February 26, 2024
·
2 min read
Business
Evogene Reports Third Quarter 2023 Financial Results
Evogene Ltd today announced its financial results for the third quarter period ended September 30, 2023.
November 15, 2023
·
18 min read
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification - March 20, 2024
Evogene Ltd. reported that the Company received a letter from the Nasdaq Stock Market LLC, indicating that the Company is currently not in compliance with Nasdaq Rule 5550, as the Company’s closing bid price for its ordinary shares has been below $1.00 per share for the last 30 consecutive business days.
March 20, 2024
·
5 min read
Press Releases
Faron Pharmaceuticals Ltd: Exercise of Options, Director Dealing and Issue of Equity
September 19, 2025
·
4 min read
Press Releases
Medicus Pharma Ltd. Completes Acquisition of Antev Limited
Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunityPatrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors
September 2, 2025
·
10 min read
1 of 7,118
Next
